Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 784670, 10 pages
http://dx.doi.org/10.1155/2013/784670
Review Article

The Role of Natriuretic Peptides for the Diagnosis of Left Ventricular Dysfunction

Department of Internal Medicine and Metabolic Diseases, Cardiology Section, Le Scotte Hospital, 53100 Siena, Italy

Received 17 June 2013; Accepted 20 August 2013

Academic Editors: X. Ai, Y. Wang, and Y. Yang

Copyright © 2013 Alberto Palazzuoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Gheorghiade and P. S. Pang, “Acute heart failure syndromes,” Journal of the American College of Cardiology, vol. 53, no. 7, pp. 557–573, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC,” European Heart Journal, vol. 33, no. 14, pp. 1787–1847, 2012. View at Publisher · View at Google Scholar
  3. J. S. Floras, “Sympathetic nervous system activation in human heart failure. Clinical implications of an updated model,” Journal of the American College of Cardiology, vol. 54, no. 5, pp. 375–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Emdin, S. Vittorini, C. Passino, and A. Clerico, “Old and new biomarkers of heart failure,” European Journal of Heart Failure, vol. 11, no. 4, pp. 331–335, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. A. Morrow and J. A. de Lemos, “Benchmarks for the assessment of novel cardiovascular biomarkers,” Circulation, vol. 115, no. 8, pp. 949–952, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. S. Vasan, “Biomarkers of cardiovascular disease: molecular basis and practical considerations,” Circulation, vol. 113, no. 19, pp. 2335–2362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Braunwald, “Medical progress: biomarkers in heart failure,” The New England Journal of Medicine, vol. 358, no. 20, pp. 2094–2159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. G. M. Felker, K. F. Adams Jr., M. A. Konstam, C. M. O'Connor, and M. Gheorghiade, “The problem of decompensated heart failure: nomenclature, classification, and risk stratification,” The American Heart Journal, vol. 145, no. 2, pp. S18–S25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gheorghiade, F. Zannad, G. Sopko et al., “Acute heart failure syndromes: current state and framework for future research,” Circulation, vol. 112, no. 25, pp. 3958–3968, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Palazzuoli and R. Nuti, “Heart failure: pathophysiology and clinical picture,” Contributions to Nephrology, vol. 164, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. R. Zile, C. F. Baicu, and W. H. Gaasch, “Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle,” The New England Journal of Medicine, vol. 350, no. 19, pp. 1953–1959, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. R. L. Shammas, N. U. A. Khan, R. Nekkanti, and A. Movahed, “Diastolic heart failure and left ventricular diastolic dysfunction: what we know, and what we don't know!,” International Journal of Cardiology, vol. 115, no. 3, pp. 284–292, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Packer, “The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure,” Journal of the American College of Cardiology, vol. 20, no. 1, pp. 248–254, 1992. View at Google Scholar · View at Scopus
  14. M. Metra, L. D. Cas, and M. R. Bristow, “The pathophysiology of acute heart failure-It is a lot about fluid accumulation,” The American Heart Journal, vol. 155, no. 1, pp. 1–5, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Meyer, M. Huelsmann, P. Wexberg et al., “N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients,” Critical Care Medicine, vol. 35, no. 10, pp. 2268–2273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Maisel, J. E. Hollander, D. Guss et al., “Primary results of the rapid emergency department heart failure outpatient trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath,” Journal of the American College of Cardiology, vol. 44, no. 6, pp. 1328–1333, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Luchner, M. Möckel, E. Spanuth et al., “N-terminal pro brain natriuretic peptide in the management of patients in the medical emergency department (PROMPT): correlation with disease severity, utilization of hospital resources, and prognosis in a large, prospective, randomized multicentre trial,” European Journal of Heart Failure, vol. 14, no. 3, pp. 259–267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Bettencourt, A. Azevedo, J. Pimenta, F. Friões, S. Ferreira, and A. Ferreira, “N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients,” Circulation, vol. 110, no. 15, pp. 2168–2174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Masson, R. Latini, I. S. Anand et al., “Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data,” Clinical Chemistry, vol. 52, no. 8, pp. 1528–1538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. R. W. Troughton, D. L. Prior, J. J. Pereira et al., “Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function,” Journal of the American College of Cardiology, vol. 43, no. 3, pp. 416–422, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. R. W. Troughton and A. M. Richards, “B-type natriuretic peptides and echocardiographic measures of cardiac structure and function,” JACC: Cardiovascular Imaging, vol. 2, no. 2, pp. 216–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Bistola, J. T. Parissis, I. Paraskevaidis et al., “Prognostic value of tissue doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy,” The American Journal of Cardiology, vol. 105, no. 2, pp. 249–254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Jourdain, G. Jondeau, F. Funck et al., “Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure. The STARS-BNP multicenter study,” Journal of the American College of Cardiology, vol. 49, no. 16, pp. 1733–1739, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Cohen-Solal, D. Logeart, B. Huang, D. Cai, M. S. Nieminen, and A. Mebazaa, “Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure,” Journal of the American College of Cardiology, vol. 53, no. 25, pp. 2343–2348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Richards, R. Doughty, M. G. Nicholls et al., “Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction,” Journal of the American College of Cardiology, vol. 37, no. 7, pp. 1781–1787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Fang, G. A. Mensah, J. B. Croft, and N. L. Keenan, “Heart Failure-Related Hospitalization in the U.S., 1979 to 2004,” Journal of the American College of Cardiology, vol. 52, no. 6, pp. 428–434, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. L. L. Lam, P. A. Cameron, H. G. Schneider, M. J. Abramson, C. Müller, and H. Krum, “Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting,” Annals of Internal Medicine, vol. 153, no. 11, pp. 728–735, 2010. View at Google Scholar · View at Scopus
  28. M. A. Silver, A. Maisel, C. W. Yancy et al., “BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases,” Congestive Heart Failure, vol. 10, no. 5, supplement 3, pp. 1–30, 2004. View at Google Scholar · View at Scopus
  29. N. Aspromonte, R. Valle, W. F. Peacock, M. Vanderheyden, and A. Maisel, “Inpatient monitoring and prognostic importance of B-type natriuretic peptide,” Congestive Heart Failure, vol. 14, no. 4, pp. 30–34, 2008. View at Google Scholar · View at Scopus
  30. A. S. Maisel, J. Koon, P. Krishnaswamy et al., “Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction,” The American Heart Journal, vol. 141, no. 3, pp. 367–374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. P. A. Heidenreich, M. A. Gubens, G. C. Fonarow, M. A. Konstam, L. W. Stevenson, and P. G. Shekelle, “Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction,” Journal of the American College of Cardiology, vol. 43, no. 6, pp. 1019–1026, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Maeda, T. Tsutamoto, A. Wada, T. Hisanaga, and M. Kinoshita, “Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction,” The American Heart Journal, vol. 135, no. 5, pp. 825–832, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Iwanaga, I. Nishi, S. Furuichi et al., “B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure,” Journal of the American College of Cardiology, vol. 47, no. 4, pp. 742–748, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. S. N. Goonewardena, J. E. A. Blair, A. Manuchehry et al., “Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization,” Journal of Cardiac Failure, vol. 16, no. 1, pp. 69–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. F. L. Dini, G. M. Rosa, P. Fontanive et al., “Combining blood flow and tissue Doppler imaging with N-terminal pro-type B natriuretic peptide for risk stratification of clinically stable patients with systolic heart failure,” European Journal of Echocardiography, vol. 11, no. 4, pp. 333–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Vinereanu, P. O. Lim, M. P. Frenneaux, and A. G. Fraser, “Reduced myocardial velocities of left ventricular long-axis contraction identify both systolic and diastolic heart failure—a comparison with brain natriuretic peptide,” European Journal of Heart Failure, vol. 7, no. 4, pp. 512–519, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. W. J. Paulus, C. Tschöpe, J. E. Sanderson et al., “How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology,” European Heart Journal, vol. 28, no. 20, pp. 2539–2550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. J. K. Oh, L. Hatle, A. J. Tajik, and W. C. Little, “Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography,” Journal of the American College of Cardiology, vol. 47, no. 3, pp. 500–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Lubien, A. DeMaria, P. Krishnaswamy et al., “Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings,” Circulation, vol. 105, no. 5, pp. 595–601, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. M. T. Maeder and D. M. Kaye, “Heart failure with normal left ventricular ejection fraction,” Journal of the American College of Cardiology, vol. 53, no. 11, pp. 905–918, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Grewal, R. McKelvie, E. Lonn et al., “BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction,” European Journal of Heart Failure, vol. 10, no. 3, pp. 252–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Tschöpe, M. Kašner, D. Westermann, R. Gaub, W. C. Poller, and H. P. Schultheiss, “The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements,” European Heart Journal, vol. 26, no. 21, pp. 2277–2284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. T. K. Lim, H. Ashrafian, G. Dwivedi, P. O. Collinson, and R. Senior, “Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: implication for diagnosis of diastolic heart failure,” European Journal of Heart Failure, vol. 8, no. 1, pp. 38–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American college of cardiology foundation/American heart association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation,” Journal of the American College of Cardiology, vol. 53, no. 15, pp. e1–e90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Guglin and H. Khan, “Pulmonary hypertension in heart failure,” Journal of Cardiac Failure, vol. 16, no. 6, pp. 461–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett Jr., “Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study,” Circulation, vol. 109, no. 25, pp. 3176–3181, 2004. View at Google Scholar · View at Scopus
  47. B. A. Groenning, I. Raymond, P. R. Hildebrandt, J. C. Nilsson, M. Baumann, and F. Pedersen, “Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population,” Heart, vol. 90, no. 3, pp. 297–303, 2004. View at Google Scholar · View at Scopus
  48. R. S. Vasan, E. J. Benjamin, M. G. Larson et al., “Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study,” The Journal of the American Medical Association, vol. 288, no. 10, pp. 1252–1259, 2002. View at Google Scholar · View at Scopus
  49. L. C. Costello-Boerrigter, G. Boerrigter, M. M. Redfield et al., “Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction,” Journal of the American College of Cardiology, vol. 47, no. 2, pp. 345–353, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. G. A. Whalley, S. P. Wright, A. Pearl et al., “Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community,” European Heart Journal, vol. 29, no. 4, pp. 509–516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. J. A. de Lemos, D. K. McGuire, A. Khera et al., “Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas heart study,” The American Heart Journal, vol. 157, no. 4, pp. 746–753, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. C. S. P. Lam, S. Cheng, K. Choong et al., “Influence of sex and hormone status on circulating natriuretic peptides,” Journal of the American College of Cardiology, vol. 58, no. 6, pp. 618–626, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. E. R. Fox, S. K. Musani, A. Bidulescu et al., “Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson heart study,” Circulation, vol. 124, no. 9, pp. 1021–1027, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett Jr., “Plasma brain natriuretic peptide concentration: impact of age and gender,” Journal of the American College of Cardiology, vol. 40, no. 5, pp. 976–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. L. B. Daniels, V. Bhalla, P. Clopton et al., “B-type natriuretic peptide (BNP) levels and ethnic disparities in perceived severity of heart failure. Results from the rapid emergency department heart failure outpatient trial (REDHOT) multicenter study of BNP levels and emergency department decision making in patients presenting with shortness of breath,” Journal of Cardiac Failure, vol. 12, no. 4, pp. 281–285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. S. M. Perman, A. M. Chang, J. E. Hollander et al., “Relationship between B-type natriuretic peptide and adverse outcome in patients with clinical evidence of sepsis presenting to the emergency department,” Academic Emergency Medicine, vol. 18, no. 2, pp. 219–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Feola, E. Lombardo, C. Taglieri, S. Piccolo, and A. Vado, “Plasma BNP and renal failure as prognostic factors of mid-term clinical outcome in congestive heart failure patients,” International Journal of Cardiology, vol. 149, no. 1, pp. 114–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Balik, A. Jabor, M. Otahal, P. Waldauf, and M. Pavlisova, “Impact of acute renal failure on the relationship between N-Terminal pro-B-type natriuretic peptide and hemodynamic parameters,” Blood Purification, vol. 31, no. 1–3, pp. 47–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. D. N. Cruz, C. Y. Goh, A. Palazzuoli et al., “Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes,” Heart Failure Reviews, vol. 16, no. 6, pp. 545–551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Tigen, T. Karaahmet, C. Cevik, E. Gurel, B. Mutlu, and Y. Basaran, “Prognostic utility of anemia and pro-B-type natriuretic peptide in patients with nonischemic dilated cardiomyopathy and normal renal function,” The American Journal of the Medical Sciences, vol. 337, no. 2, pp. 109–115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Palazzuoli, D. S. Silverberg, F. Iovine et al., “Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome,” The American Heart Journal, vol. 154, no. 4, pp. 645.e9–645.e15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. R. R. J. van Kimmenade, Y. M. Pinto, A. Bayes-Genis, J. G. Lainchbury, A. M. Richards, and J. L. Januzzi Jr., “Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure,” The American Journal of Cardiology, vol. 98, no. 3, pp. 386–390, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. C. K. Brenden, J. E. Hollander, D. Guss et al., “Gray zone BNP levels in heart failure patients in the emergency department: results from the rapid emergency department heart failure outpatient trial (REDHOT) multicenter study,” The American Heart Journal, vol. 151, no. 5, pp. 1006–1011, 2006. View at Google Scholar · View at Scopus
  64. G. Parrinello, D. Torres, S. Paterna, P. Di Pasquale, and G. Licata, “Wet BNP, fluid and hemodynamic status at discharge in acute heart failure,” International Journal of Cardiology, vol. 145, no. 2, pp. 335–336, 2010. View at Publisher · View at Google Scholar · View at Scopus